Kenvue (KVUE) DIvidends Date & History

Key Takeaways

• Kenvue pays a quarterly dividend of $0.2075 per share, annualized to about $0.83, for a trailing yield of roughly 4.5%.
• The dividend has been raised three years in a row since the company's 2023 spinoff from Johnson & Johnson, though annual increases have been modest (about 1%–2.5%).
• The earnings-based payout ratio is elevated (near or above 100% on trailing EPS), but free cash flow coverage is far more comfortable, reflecting heavy non-cash and restructuring charges.
• The yield sits well above the consumer staples average, in part because the share price has declined, which appeals to income investors but signals elevated risk.

Dividend Overview

Kenvue (NYSE: KVUE) is the world's largest pure-play consumer health company, formed in May 2023 when Johnson & Johnson spun off its consumer segment. Its portfolio includes brands such as Tylenol, Band-Aid, Neutrogena, Listerine, and Aveeno.

Since its market debut, Kenvue has paid a quarterly dividend, currently $0.2075 per share, which annualizes to about $0.83. At recent share prices, that translates to a dividend yield of roughly 4.5% — high by consumer staples standards. The company initiated its dividend at $0.20 per share in 2023 and has raised it in each subsequent year. Kenvue is best described as an early-stage dividend payer with an above-average yield, rather than a long-established dividend growth or dividend aristocrat stock.

Dividend History and Growth

Kenvue's dividend track record is short but consistent. The company began paying $0.20 per share shortly after its 2023 spinoff, increased the payout to $0.205 in 2024, and raised it again to $0.2075 in mid-2025 — a pattern of small, steady annual increases. Over the trailing twelve months, dividend growth has been about 1.2%, modest relative to faster-growing peers.

Because Kenvue has only paid dividends since 2023, it does not yet carry a long-term dividend growth streak. Management has framed the dividend as part of a balanced capital-allocation strategy that also prioritizes debt reduction and reinvestment in its brands. For now, investors should view Kenvue as a modest dividend grower still building its payout history rather than a proven compounder.

Dividend Sustainability and Payout Ratio

Sustainability is the central question for Kenvue's dividend. On a trailing earnings basis, the payout ratio is elevated — several data providers report figures near or above 100% of earnings per share (EPS). However, that headline number is distorted by significant non-cash and restructuring charges tied to the spinoff and brand-optimization efforts.

Measured against free cash flow, the picture is more reassuring: the cash-flow payout ratio is estimated at roughly 60% to 87%, depending on the cash-flow measure used. Kenvue's consumer health franchises generate reliable, defensive cash flow, which underpins the dividend even when reported earnings are temporarily depressed. A moderate debt load following the spinoff remains a watch item, but the company's recession-resistant categories and strong brand portfolio provide a stable foundation for continued quarterly payments.

Dividend Compared to Industry Peers

Within household and personal products, Kenvue's ~4.5% yield is notably higher than established rivals. Procter & Gamble yields around 2%, Colgate-Palmolive roughly 2%, Kimberly-Clark near 3%, and Church & Dwight just over 1%.

The gap cuts both ways. Those peers offer far longer dividend growth streaks — in some cases several decades — while Kenvue compensates with a higher current yield. Kenvue's elevated yield partly reflects a lower share price rather than an exceptionally generous payout policy. Investors effectively trade a long, proven track record for higher immediate income and a shorter, still-developing dividend history.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, and breakout candidates far more efficiently than manual screening. Whether you are seeking high-yield income names like Kenvue or building a diversified watchlist, the AI Screener can streamline the research process and surface opportunities tailored to your criteria.

Is This Stock Attractive for Dividend Investors?

Kenvue may appeal primarily to income-oriented investors who prioritize a high current yield and are comfortable with a relatively short dividend history. Its defensive consumer health categories, iconic brands, and strong cash generation make it a candidate for long-term, conservative portfolios seeking steady quarterly income.

That said, the stock is less suited to pure dividend-growth investors who seek rapid payout increases and multi-decade growth streaks; Kenvue's annual raises have been small, and its earnings-based payout ratio remains elevated. The elevated yield partly reflects share-price weakness, meaning capital preservation and dividend coverage depend on successful execution of the company's post-spinoff turnaround. As with any income investment, the dividend is not guaranteed, and investors should weigh the high yield against the company's still-maturing earnings profile and balance-sheet considerations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations